Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes

Arthritis Research and Therapy

Volumn 12, Issue 4, 2010, Pages

  Calamia, Valentina ^a   Ruiz Romero, Cristina ^a   Rocha, Beatriz ^a   Fernández Puente, Patricia ^a   Mateos, Jesús ^a   Montell, Eulàlia ^b   Vergés, Josep ^b   Blanco, Francisco J ^a  

^a UNIVERSITY OF A CORUÑA   (Spain)

^b BIOIBERICA SA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN; GLUCOSAMINE SULFATE; INTERLEUKIN 1BETA; MANGANESE SUPEROXIDE DISMUTASE; REDOX EFFECTOR FACTOR 1; CHONDROITIN SULFATE; GLUCOSAMINE; SUPEROXIDE DISMUTASE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARTILAGE CELL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PROTEIN FOLDING; PROTEIN SYNTHESIS; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STRESS; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING; CARTILAGE; CELL CULTURE; CYTOLOGY; GENETICS; IMMUNOLOGY; KNEE; KNEE OSTEOARTHRITIS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

CARTILAGE; CELLS, CULTURED; CHONDROCYTES; CHONDROITIN SULFATES; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GLUCOSAMINE; HUMANS; INTERLEUKIN-1BETA; KNEE JOINT; OSTEOARTHRITIS, KNEE; PROTEOMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SUPEROXIDE DISMUTASE;

EID: 77954401191     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3077     Document Type: Article

References (55)

1. Berenbaum F. New horizons and perspectives in the treatment of osteoarthritis. Arthritis Res Ther 2008, 10:S1. 10.1186/ar2462, 2582808, 19007426.
2. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE, Gossett C. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001, 357:251-256. 10.1016/S0140-6736(00)03610-2, 11214126.
3. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002, 162:2113-2123. 10.1001/archinte.162.18.2113, 12374520.
4. Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, Hochberg MC, Wells G. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005, CD002946.
5. Leeb BF, Schweitzer H, Montag K, Smolen JS. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000, 27:205-211.
6. Kahan A, Uebelhart D, De Vathaire F, Delmas PD, Reginster JY. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009, 60:524-533. 10.1002/art.24255, 19180484.
7. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000, 283:1469-1475. 10.1001/jama.283.11.1469, 10732937.
8. Reichenbach S, Sterchi R, Scherer M, Trelle S, Bürgi E, Bürgi U, Dieppe PA, Jüni P. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007, 146:580-590.
9. Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham CO, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW, Williams HJ. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006, 354:795-808. 10.1056/NEJMoa052771, 16495392.
10. Gouze JN, Gouze E, Popp MP, Bush ML, Dacanay EA, Kay JD, Levings PP, Patel KR, Saran JP, Watson RS, Ghivizzani SC. Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1beta. Arthritis Res Ther 2006, 8:R173. 10.1186/ar2082, 1794517, 17109745.
11. Chapal N, Molina L, Molina F, Laplanche M, Pau B, Petit P. Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer. Fundam Clin Pharmacol 2004, 18:413-422. 10.1111/j.1472-8206.2004.00258.x, 15312147.
12. Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004, 4:3665-3685. 10.1002/pmic.200401031, 15543535.
13. Ruiz-Romero C, Lopez-Armada MJ, Blanco FJ. Proteomic characterization of human normal articular chondrocytes: a novel tool for the study of osteoarthritis and other rheumatic diseases. Proteomics 2005, 5:3048-3059. 10.1002/pmic.200402106, 16035116.
14. Ruiz-Romero C, Carreira V, Rego I, Remeseiro S, Lopez-Armada MJ, Blanco FJ. Proteomic analysis of human osteoarthritic chondrocytes reveals protein changes in stress and glycolysis. Proteomics 2008, 8:495-507. 10.1002/pmic.200700249, 18186017.
15. Cillero-Pastor B, Ruiz-Romero C, Caramés B, López-Armada MJ, Blanco FJ. Two-dimensional electrophoresis proteomic analysis to identify the normal human chondrocyte proteome stimulated by tumor necrosis factor-alpha and interleukin-1beta. Arthritis Rheum 2010, 62:802-814. 10.1002/art.27265, 20131227.
16. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002, 39:237-246. Review.
17. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685. 10.1038/227680a0, 5432063.
18. Rabilloud T, Brodard V, Peltre G, Righetti PG, Ettori C. Modified silver staining for immobilized pH gradients. Electrophoresis 1992, 13:264-266. 10.1002/elps.1150130154, 1628608.
19. Sechi S, Chait BT. Modification of cysteine residues by alkylation. A tool in peptide mapping and protein identification. Anal Chem 1998, 70:5150-5158. 10.1021/ac9806005, 9868912.
20. Matrix Science. , http://www.matrixscience.com
21. ExPASy Proteomics Server. , http://www.expasy.ch/sprot
22. UniProt Knowledgebase. , http://www.ebi.ac.uk/trembl
23. PSORT II Prediction. , http://www.psort.org/
24. Universal ProbeLibrary System. , http://www.roche-applied-science.com
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
26. Ruiz-Romero C, Calamia V, Mateos J, Carreira V, Martinez-Gomariz M, Fernandez M, Blanco FJ. Mitochondrial dysregulation of osteoarthritic human articular chondrocytes analyzed by proteomics: a decrease in mitochondrial superoxide dismutase points to a redox imbalance. Mol Cell Proteomics 2009, 8:172-189. 10.1074/mcp.M800292-MCP200, 2713027, 18784066.
27. Shikhman AR, Kuhn K, Alaaeddine N, Lotz M. N-acetylglucosamine prevents IL-1 beta-mediated activation of human chondrocytes. J Immunol 2001, 166:5155-5160.
28. Gouze JN, Bianchi A, Becuwe P, Dauca M, Netter P, Magdalou J, Terlain B, Bordji K. Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-kappa B pathway. FEBS Lett 2002, 510:166-170. 10.1016/S0014-5793(01)03255-0, 11801247.
29. Tat SK, Pelletier JP, Vergés J, Lajeunesse D, Montell E, Fahmi H, Lavigne M, Martel-Pelletier J. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. Arthritis Res Ther 2007, 9:R117. 10.1186/ar2325, 2246236, 17996099.
30. Iovu M, Dumais G, du Souich P. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 2008, 16:S14-18. 10.1016/j.joca.2008.06.008, 18667340.
31. Uldry M, Ibberson M, Hosokawa M, Thorens B. GLUT2 is a high affinity glucosamine transporter. FEBS Lett 2002, 524:199-203. 10.1016/S0014-5793(02)03058-2, 12135767.
32. Windhaber RA, Wilkins RJ, Meredith D. Functional characterisation of glucose transport in bovine articular chondrocytes. Pflugers Arch 2003, 446:572-577. 10.1007/s00424-003-1080-5, 12750890.
33. David-Raoudi M, Mendichi R, Pujol JP. For intra-articular delivery of chondroitin sulphate. Glycobiology 2009, 19:813-815. 10.1093/glycob/cwp069, 19487725.
34. Wei F, Haut RC. High levels of glucosamine-chondroitin sulfate can alter the cyclic preload and acute overload responses of chondral explants. J Orthop Res 2009, 27:353-359. 10.1002/jor.20757, 18925654.
35. d'Abusco AS, Calamia V, Cicione C, Grigolo B, Politi L, Scandurra R. Glucosamine affects intracellular signalling through inhibition of mitogen-activated protein kinase phosphorylation in human chondrocytes. Arthritis Res Ther 2007, 9:R104. 10.1186/ar2307, 2212570, 17925024.
36. Chan PS, Caron JP, Orth MW. Effects of glucosamine and chondroitin sulfate on bovine cartilage explants under long-term culture conditions. Am J Vet Res 2007, 68:709-715. 10.2460/ajvr.68.7.709, 17605605.
37. Piperno M, Reboul P, Hellio Le Graverand MP, Peschard MJ, Annefeld M, Richard M, Vignon E. Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthritis Cartilage 2000, 8:207-212. 10.1053/joca.1999.0291, 10806048.
38. Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 1998, 6:14-21. 10.1016/S1063-4584(98)80006-X, 9743814.
39. Chan PS, Caron JP, Orth MW. Short-term gene expression changes in cartilage explants stimulated with interleukin beta plus glucosamine and chondroitin sulfate. J Rheumatol 2006, 33:1329-1340.
40. Orth MW, Peters TL, Hawkins JN. Inhibition of articular cartilage degradation by glucosamine-HCl and chondroitin sulphate. Equine Vet J Suppl 2002, 34:224-229. 10.1111/j.2042-3306.2002.tb05423.x, 12405691.
41. Chou MM, Vergnolle N, McDougall JJ, Wallace JL, Marty S, Teskey V, Buret AG. Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloprotease-9, and cartilage damage in arthritis. Exp Biol Med (Maywood) 2005, 230:255-262.
42. Chan PS, Caron JP, Rosa GJ, Orth MW. Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants. Osteoarthritis Cartilage 2005, 13:387-394. 10.1016/j.joca.2005.01.003, 15882562.
43. Campo GM, Avenoso A, Campo S, Ferlazzo AM, Altavilla D, Calatroni A. Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats. Arthritis Res Ther 2003, 5:R122-131. 10.1186/ar748, 165044, 12723984.
44. Legendre F, Baugé C, Roche R, Saurel AS, Pujol JP. Chondroitin sulfate modulation of matrix and inflammatory gene expression in IL-1beta-stimulated chondrocytes--study in hypoxic alginate bead cultures. Osteoarthritis Cartilage 2008, 16:105-114. 10.1016/j.joca.2007.05.020, 17625924.
45. David-Raoudi M, Deschrevel B, Leclercq S, Galéra P, Boumediene K, Pujol JP. Chondroitin sulfate increases hyaluronan production by human synoviocytes through differential regulation of hyaluronan synthases: Role of p38 and Akt. Arthritis Rheum 2009, 60:760-770. 10.1002/art.24302, 19248106.
46. Grimmer C, Balbus N, Lang U, Aigner T, Cramer T, Müller L, Swoboda B, Pfander D. Regulation of Type II Collagen Synthesis during Osteoarthritis by Prolyl-4-Hydroxylases. Am J Pathol 2006, 169:491-502. 10.2353/ajpath.2006.050738, 1698781, 16877351.
47. Ellgaard L, Frickel EM. Calnexin, calreticulin, and ERp57: teammates in glycoprotein folding. Cell Biochem Biophys 2003, 39:223-247. 10.1385/CBB:39:3:223, 14716078.
48. Kivirikko KI, Pihlajaniemi T. Collagen hydroxylases and the protein disulfide isomerase subunit of prolyl 4-hydroxylases. Adv Enzymol Relat Areas Mol Biol 1998, 72:325-398.
49. Alexopoulos LG, Youn I, Bonaldo P, Guilak F. Developmental and osteoarthritic changes in Col6a1-knockout mice: biomechanics of type VI collagen in the cartilage pericellular matrix. Arthritis Rheum 2009, 60:771-779. 10.1002/art.24293, 2724839, 19248115.
50. Corrigall VM, Bodman-Smith MD, Fife MS, Canas B, Myers LK, Wooley P, Soh C, Staines NA, Pappin DJ, Berlo SE, van Eden W, van Der Zee R, Lanchbury JS, Panayi GS. The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J Immunol 2001, 166:1492-1498.
51. Panayi GS, Corrigall VM. BiP regulates autoimmune inflammation and tissue damage. Autoimmun Rev 2006, 5:140-142. 10.1016/j.autrev.2005.08.006, 16431346.
52. Matthews JA, Belof JL, Acevedo-Duncan M, Potter RL. Glucosamine-induced increase in Akt phosphorylation corresponds to increased endoplasmic reticulum stress in astroglial cells. Mol Cell Biochem 2007, 298:109-123. 10.1007/s11010-006-9358-5, 17136481.
53. Marshall KW, Zhang H, Yager TD, Nossova N, Dempsey A, Zheng R, Han M, Tang H, Chao S, Liew CC. Blood-based biomarkers for detecting mild osteoarthritis in the human knee. Osteoarthritis Cartilage 2005, 13:861-871. 10.1016/j.joca.2005.06.002, 16139532.
54. Afonso V, Champy R, Mitrovic D, Collin P, Lomri A. Reactive oxygen species and superoxide dismutases: role in joint diseases. Joint Bone Spine 2007, 74:324-329. Review, 10.1016/j.jbspin.2007.02.002, 17590367.
55. Valvason C, Musacchio E, Pozzuoli A, Ramonda R, Aldegheri R, Punzi L. Influence of glucosamine sulphate on oxidative stress in human osteoarthritic chondrocytes: effects on HO-1, p22(Phox) and iNOS expression. Rheumatology (Oxford) 2008, 47:31-35. 10.1093/rheumatology/kem289, 18077487.